Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist / 임상당뇨병
Journal of Korean Diabetes
; : 149-156, 2019.
Article
em Ko
| WPRIM
| ID: wpr-761490
Biblioteca responsável:
WPRO
ABSTRACT
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Peso Corporal
/
Doenças Cardiovasculares
/
Redução de Peso
/
Incidência
/
Acidente Vascular Cerebral
/
Diabetes Mellitus
/
Insuficiência Renal Crônica
/
Peptídeo 1 Semelhante ao Glucagon
/
Liraglutida
/
Receptor do Peptídeo Semelhante ao Glucagon 1
Tipo de estudo:
Guideline
/
Incidence_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
Ko
Revista:
Journal of Korean Diabetes
Ano de publicação:
2019
Tipo de documento:
Article